Part I Overview We are a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare and severe diseases of the front and back of the eye. Our product candidate, KPI-012, which we acquired from Combangio, Inc., or Combangio, on November 15, 2021, is a mesenchymal stem cell secretome, or MSC-S, and is currently in clinical development for the treatment of persistent corneal epithelial defects, or PCED, a rare disease of im...
Q2 FY2026 — expected 2026-09-19
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-03-31 | 2024-12-31 | 0001558370-25-004081 | EDGAR | 138K words |
| 2024-03-29 | 2023-12-31 | 0001558370-24-004326 | EDGAR | — |
| 2023-03-03 | 2022-12-31 | 0001558370-23-002746 | EDGAR | — |
| 2022-03-29 | 2021-12-31 | 0001558370-22-004624 | EDGAR | — |
| 2021-02-25 | 2020-12-31 | 0001558370-21-001797 | EDGAR | — |
| 2020-02-12 | 2019-12-31 | 0001558370-20-000733 | EDGAR | — |
| 2019-03-12 | 2018-12-31 | 0001558370-19-001825 | EDGAR | — |
| 2018-04-02 | 2017-12-31 | 0001558370-18-002697 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-11-19 | 2025-09-30 | 0001104659-25-113927 | EDGAR | 35K words |
| 2025-08-08 | 2025-06-30 | 0001558370-25-010853 | EDGAR | — |
| 2025-05-14 | 2025-03-31 | 0001558370-25-007763 | EDGAR | — |
| 2024-11-12 | 2024-09-30 | 0001558370-24-015302 | EDGAR | — |
| 2024-08-06 | 2024-06-30 | 0001558370-24-011074 | EDGAR | — |
| 2024-05-14 | 2024-03-31 | 0001558370-24-008134 | EDGAR | — |
| 2023-11-13 | 2023-09-30 | 0001558370-23-018696 | EDGAR | — |
| 2023-08-04 | 2023-06-30 | 0001558370-23-013310 | EDGAR | — |
| 2023-05-09 | 2023-03-31 | 0001558370-23-008798 | EDGAR | — |
| 2022-11-08 | 2022-09-30 | 0001558370-22-016848 | EDGAR | — |
| 2022-08-11 | 2022-06-30 | 0001558370-22-013308 | EDGAR | — |
| 2022-05-16 | 2022-03-31 | 0001558370-22-008970 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-07-23 | 0001829126-26-007760 | EDGAR | — |
| 2026-03-04 | 0001829126-26-001911 | EDGAR | 11K words |
| 2026-02-20 | 0001829126-26-001534 | EDGAR | — |
| 2026-02-05 | 0001829126-26-000995 | EDGAR | — |
| 2026-02-02 | 0001829126-26-000837 | EDGAR | — |
| 2026-01-23 | 0001829126-26-000502 | EDGAR | — |
| 2026-01-08 | 0001829126-26-000110 | EDGAR | — |
| 2026-01-06 | 0001829126-26-000055 | EDGAR | — |
| 2026-01-02 | 0001829126-26-000023 | EDGAR | — |
| 2025-12-29 | 0001829126-25-010330 | EDGAR | — |
184 total filings indexed. 154 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001479419 |
| Ticker | KALA |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | DE |
| Website | https://www.kalarx.com |
| Listed | 2017-07-20 |
This is a static snapshot. For live, structured JSON with cryptographic provenance chain:
MCP (recommended for AI): claude mcp add origin --transport http https://origin.rootz.global/mcp
Try it — paste this into your AI:
Works in ChatGPT, Claude, Gemini, or any AI. Free, structured, cryptographically signed — ~500 tokens vs 130,000 scraping an IR site.
claude mcp add origin --transport http https://origin.rootz.global/mcpGET https://origin.rootz.global/api/company/KALA (~200 tokens, structured JSON with cryptographic provenance)